Lovastatin Enhances Clearance of Apoptotic Cells (Efferocytosis) with Implications for Chronic Obstructive Pulmonary Disease

Konosuke Morimoto,*, William J. Janssen,† Michael B. Fessler,† Kathleen A. McPhillips,‡ Valeria M. Borges,‡ Russell P. Bowler,† Yi-Qun Xiao,‡ Jennifer A. Kench,‡ Peter M. Henson,‡ and R. William Vandivier2*

Statins are potent, cholesterol-lowering agents with newly recognized, broad anti-inflammatory properties (1). For example, statins suppress the innate immune response in vitro by inhibiting neutrophil migration (2), oxidative stress (3), NF-κB activation (4), proinflammatory mediator release (5, 6), expression of matrix metalloproteinases (7–9), and by increasing expression of constitutive NO synthase (10), peroxisome proliferator-activated receptor (PPAR)α (11), PPARγ (4), and TGFβ1 (12). Statins also suppress the adaptive immune response by inhibiting IFN-γ-inducible MHC class II expression (13), decreasing expression of CD40/CD40L (14), and by direct blockade of LFA-1 (15). These pleiotropic, anti-inflammatory effects have important therapeutic implications, because 1) statins effectively treat animal models of sepsis, rheumatoid arthritis, acute lung injury, asthma, and emphysema (2, 16–19), and 2) clinically, statins have a promising therapeutic role in the acute coronary syndrome, stabilization of carotid artery plaques, sepsis syndrome, lung allograft rejection, and rheumatoid arthritis (7, 20–24). Therefore, statins appear to be emerging as a new class of immunomodulators, surpassing their originally envisaged role as cholesterol lowering drugs.

The immunomodulatory effects of statins are largely cholesterol independent; instead, they appear to depend upon the ability of statins to posttranslationally modify an extensive array of intracellular signaling molecules, including the Rho family of GTPases (1). Rho GTPases (e.g., RhoA, Rac-1, and Cdc42) are molecular switches, which for function, depend upon the covalent attachment of lipid adducts (prenylation) that direct membrane insertion, localization, and protein:protein interaction (25, 26). Statins regulate prenylation of Rho GTPases by blocking 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase-dependent manner. These findings indicate that statins enhance efferocytosis in vitro and in vivo, and suggest that they may play an important therapeutic role in diseases where efferocytosis is impaired and inflammation is dysregulated. The Journal of Immunology, 2006, 176: 7657–7665.
because it is defective in systemic lupus erythematosus, rheumatoid arthritis, cystic fibrosis, bronchiectasis, asthma, and chronic obstructive pulmonary disease (COPD) (31–37). The regulation of effectorcytosis is tightly controlled by the Rho family GTPTases, in that RhoA inhibits (38–40) and Rac-1/Cdc42/RhoG promotes (41–43) the process. Because statins robustly inhibit RhoA, a negative regulator of effectorcytosis, we hypothesized that statins would enhance effectorcytosis, and sought to determine whether statins might have therapeutic potential in COPD, a disease of impaired effectorcytosis (31, 32).

Indeed, our data demonstrate that statins are potent inducers of effectorcytosis in vitro and in vivo in an HMG CoA-reductase dependent manner. Statins appear to exert their effect, not by suppressing cholesterol, but by disproportionately suppressing the prenylation and membrane localization of RhoA. Finally, these data may have therapeutic implications for the treatment of chronic inflammatory diseases of the lung, because statins augment effectorcytosis in the naïve murine lung and in alveolar macrophages obtained from patients with COPD.

Materials and Methods

Human subjects

The study was approved by, and performed in accordance with, the ethical standards of the institutional review board on human experimentation at National Jewish Medical and Research Center. Written informed consent was obtained from each subject.

Experimental animals

Mice were housed and studied under institutional animal care and use committee-approved protocols in the animal facility of National Jewish Medical and Research Center. Experiments were performed on 8- to 12-wk-old, age-matched, female ICR mice (Harlan Sprague Dawley).

Primary cell isolation and culture

Human monocyte-derived macrophages (HMDMs) and neutrophils were isolated and prepared from normal blood, as previously described (44). HMDMs were cultured in X-vivo medium (Cambrex BioScience) with 10% pooled human serum at 37°C in 10% CO₂ for 7 days before use.

Human alveolar macrophages were isolated by bronchoalveolar lavage from patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 COPD as described (31, 45). Briefly, mice were anesthetized with Avertin, following the indicated times: mevalonate (Sigma-Aldrich), GGPP (Sigma-Aldrich), and FPP (Sigma-Aldrich). Inhibitors of farnesyltransferase (FTI-276; Calbiochem-Novabiochem) and geranylgeranyltransferase I (GGTI-2133; Calbiochem-Novabiochem) were added to HMDMs 8 h before experimentation. FTI-276 inhibits farnesyltransferase with an IC₅₀ of 0.5 nM, and GGTI-2133 inhibits geranylgeranyltransferase I with an IC₅₀ of 38 nM, and farnesyltransferase at a much higher IC₅₀ of 5.4 μM.

In vivo phagocytosis assays

To test the effect of lovastatin and mevalonate on uptake of apoptotic cells, mice were divided into four groups and treated as follows: 1) control group, treated with vehicle (0.5% carboxymethylcellulose sodium, 0.9% sodium chloride, 0.4% polysorbate 80, 0.9% benzyl alcohol in deionized water) by gavage and PBS by i.p. injection; 2) lovastatin group, treated with lovastatin (10 mg/kg) in vehicle by gavage and PBS by i.p. injection; 3) mevalonate group, treated with vehicle by gavage and 10 mg/kg mevalonate by i.p. injection; 4) lovastatin/mevalonate group, treated with lovastatin (10 mg/kg) in vehicle by gavage and mevalonate (10 mg/kg) by i.p. injection. Mice were treated three times, spaced within 30 h, before the time of experimentation.

Statins activate apoptotic thymocytes were instilled intratracheally as previously described (31). Briefly, mice were anesthetized with Avertin, following the indicated times: mevalonate (Sigma-Aldrich), GGPP (Sigma-Aldrich), and FPP (Sigma-Aldrich). Inhibitors of farnesyltransferase (FTI-276; Calbiochem-Novabiochem) and geranylgeranyltransferase I (GGTI-2133; Calbiochem-Novabiochem) were added to HMDMs 8 h before experimentation. FTI-276 inhibits farnesyltransferase with an IC₅₀ of 0.5 nM, and GGTI-2133 inhibits geranylgeranyltransferase I with an IC₅₀ of 38 nM, and farnesyltransferase at a much higher IC₅₀ of 5.4 μM.

In vitro phagocytosis assays

Phagocytic assays were performed on day 7 HMDMs, as previously described (31). Briefly, apoptotic human neutrophils were added to HMDMs at a 5:1 ratio (apoptotic cell to HMDM) and incubated at 37°C in 10% CO₂ for 40 min in 500 μl of X-Vivo medium. HMDMs were washed gently with cold PBS to remove unengested cells, fixed, and stained with a modified Wright-Giemsa stain (Fisher Scientific). Phagocytosis was determined by visual inspection of samples and was expressed as the phagocytic index (PI), as described (49). Each condition was tested in duplicate and a minimum of 400 HMDMs were counted per condition. In all cases, during analysis, the reader was blinded to the sample identification.

HMDMs were pretreated with 0–10 μM lovastatin for 4–120 h before experimentation. Phagocytosis assays were then performed in the presence and absence of the following reagents at the indicated concentrations: for the indicated times: mevalonate (Sigma-Aldrich), GGPP (Sigma-Aldrich), and FPP (Sigma-Aldrich). Inhibitors of farnesyltransferase (FTI-276; Calbiochem-Novabiochem) and geranylgeranyltransferase I (GGTI-2133; Calbiochem-Novabiochem) were added to HMDMs 8 h before experimentation. FTI-276 inhibits farnesyltransferase with an IC₅₀ of 0.5 nM, and GGTI-2133 inhibits geranylgeranyltransferase I with an IC₅₀ of 38 nM, and farnesyltransferase at a much higher IC₅₀ of 5.4 μM.
polyclonal anti-human calreticulin IgY (American Diagnostica) Abs include mouse monoclonal anti-human α-chain CD91 IgG1. Mouse monoclonal anti-human PS recognition structure IgM (217) was prepared in this laboratory as previously described (27). Jackson ImmunoResearch Laboratories Abs include chicken IgY isotype control, Cy-3 goat IgG anti-mouse IgM, and Cy-3 goat IgG anti-mouse IgG, and Cy-3 goat anti-chicken IgY.

Western blotting
HMMD membrane fractions were prepared and separated on SDS-PAGE as described previously (51, 52). Briefly, HMMDs plated on 10-cm tissue-culture dish were harvested and resuspended in PBS. Pelleted cells were lysed by Reporter Lysis Buffer (Promega) and by repeated freeze-thaw cycles. Cell lysates were spun down at 3,000 rpm for 10 min. Supernatants were collected and spun-down at 10,000 × g for 45 min. The pellet was solubilized in lystate buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM DTT, 1% Triton X-100). Samples were run on a 7.5% SDS-PAGE gel, transferred to nitrocellulose, blocked with 3% milk, and sequentially incubated with primary and secondary Abs. Total protein was measured by the BCA Protein Assay kit (Pierce) and equivalent amounts were loaded. Membranes were developed using Amersham ECL system and immunodetection was accomplished using a mouse anti-mouse HRP-conjugated secondary Ab (clone 23A8, 1/10,000). Membranes were developed using Amersham ECL System (Amersham Biosciences).

Statistics
The means were analyzed using ANOVA for multiple comparisons; when ANOVA indicated significance, the Dunnett’s method was used to compare groups with an internal control. For all other experiments in which two conditions were being compared, a Student’s t test assuming equal variance was used. All data were analyzed using JMP (version 3) Statistical Software for Macintosh (SAS Institute) and are presented ± SEM.

Results
Lovastatin increases uptake of apoptotic cells (efferocytosis)
We tested the effect of statins on efferocytosis by incubating HMDMs with lovastatin for 6–48 h. Lovastatin (5 μM) increased efferocytosis as early as 6 h (Fig. 1B). However, at 24 h, lovastatin increased efferocytosis in a dose-dependent fashion, exerting a maximum effect at 10 μM. In contrast, lovastatin had no effect on binding of apoptotic cells to HMDMs (Fig. 1C). Lovastatin (1 μM) also increased efferocytosis in HMDMs after 5 days of treatment compared with untreated controls, suggesting that the effect was prolonged (Fig. 1D).

The effect of lovastatin on efferocytosis is dependent on HMG-CoA reductase
Most, but not all, statin effects are related to their ability to competitively block HMG-CoA reductase, and thereby decrease production of multiple intermediates in the cholesterol biosynthetic pathway. Mevalonate is the initial product of HMG-CoA reductase (Fig. 1A) and mevalonate levels are decreased by statin treatment. We performed “rescue” experiments with mevalonate to determine whether lovastatin was acting through an HMG-CoA reductase-dependent pathway (Fig. 1E). Mevalonate reversed the ability of lovastatin to potentiate efferocytosis, confirming HMG-CoA reductase dependency. In contrast, lovastatin suppressed phagocytosis of IgG-opsonized erythrocytes through the FcγR, as has recently been shown (53, 54), and this also appeared to be dependent on HMG-CoA reductase (Fig. 1F).

Lovastatin does not affect expression of efferocytosis receptors
We considered that lovastatin may exert its positive effect on efferocytosis by increasing expression of key uptake receptors, especially because statins were recently reported to increase the expression of CD36, a well-known efferocytosis receptor (55). Contrary to this report, we found that lovastatin had no effect on expression of HMDM efferocytosis receptors (i.e., αvβ3, β3, CD91, calreticulin, CD36, CD44, CD14) or the FcγRIIA (Fig. 2). Lovastatin also had no effect on staining by mAb 217. The protein target of mAb 217 was originally thought to be the phosphatidylserine receptor, but is now not known.

Lovastatin-enhanced efferocytosis is dependent on prenylation
Statins regulate the posttranslational modification of hundreds of proteins by controlling the production of key substrates of protein prenylation, such as FPP and GGPP. Because mevalonate is an upstream precursor of both FPP and GGPP, statins ultimately decrease their levels as well. We performed dose-response rescue experiments with GGPP and FPP, and found that both reversed lovastatin-enhanced efferocytosis, albeit with different potencies (Fig. 3, A and B). Even though these experiments suggested a role for both farnesylation and geranylgeranylation, they did not rule out the possibility that the effect of FPP was due to its conversion to GGPP and augmentation of geranylgeranylation. This is an important issue because the known Rho GTPase regulators of efferocytosis are only geranylgeranylated. Incomplete inhibition of HMG-CoA reductase could potentially allow low level synthesis of the 5-carbon isopentenyl pyrophosphate (IPP), which normally condenses with 15-carbon FPP to produce 20-carbon GGPP (Fig. 1A), thereby creating a pathway for FPP repletion to influence geranylgeranylation.

Specific inhibitors of geranylgeranyltransferase I (GGTI-2133; IC50 = 38 nM) and farnesyltransferase (FTI-276; IC50 = 0.5 μM) were used to further examine the role of these separate prenylation pathways on efferocytosis. Both inhibitors enhanced efferocytosis, but the effect of FTI-276 appeared to be more modest than GGTI-2133 (Fig. 3, C and D). It is important to note that farnesyltransferase inhibitors may increase the production of geranylgeranylated proteins, presumably by shunting excess FPP to GGPP (56). This suggests that farnesyltransferase inhibitors may not solely act by decreasing farnesylated proteins, but instead they may also change the balance in favor of geranylgeranylated proteins. Consistent with this possibility, combinations of GGTI-2133 and FTI-276 did not enhance efferocytosis more than lovastatin or GGTI-2133 alone (data not shown). Therefore, efferocytosis appears to be regulated by intracellular signaling molecules that are geranylgeranylated, and possibly by those that are farnesylated.

Lovastatin suppresses membrane-bound RhoA greater than Rac-1
Statins inhibit prenylation and membrane localization of a variety of Rho GTPases, including positive (Rac-1) and negative (RhoA) regulators of efferocytosis. Yet, in HMDMs, lovastatin consistently enhanced efferocytosis, implying that lovastatin may exert a prolonged, disproportionate effect on the prenylation and membrane localization of RhoA. To address this hypothesis, HMDMs were treated with and without lovastatin for 24 h, and membrane fractions were assessed for RhoA and Rac-1 staining by Western blot. Lovastatin decreased membrane-bound RhoA greater than Rac-1 (Fig. 4, A and B), suggesting a mechanism for the positive effect of lovastatin on efferocytosis.

Lovastatin reverses impaired efferocytosis by lysophosphatidic acid (LPA), a potent RhoA activator
We next used the potent RhoA activator, LPA to address whether lovastatin could reverse impaired efferocytosis in vitro (57). LPA-suppressed efferocytosis by HMDMs, and this suppression was prevented by lovastatin (Fig. 4C), suggesting that lovastatin, or for that matter other Rho pathway inhibitors, could play a therapeutic role in efferocytosis.
role in diseases where suppression of efferocytosis contributes to disease pathogenesis.

**Lovastatin increases efferocytosis in vivo**

We tested whether statins could enhance efferocytosis by treating mice with lovastatin (10 mg/kg) three times over 30 h. Ten million, Cell Tracker Red-labeled apoptotic murine thymocytes were then instilled intratracheally and clearance was assessed. This model has previously been used to evaluate efferocytosis by macrophages and epithelial cells in vivo (45, 50). Defective efferocytosis is suggested by either decreased uptake into alveolar macrophages (i.e., decreased PI; Fig. 5A), or by increased recovery of apoptotic cells in the bronchoalveolar lavage (Fig. 5B). Lovastatin modestly increased efferocytosis in the naive murine lung as measured by an increase in the alveolar macrophage PI (Fig. 5C) and by a decrease in the recovery of apoptotic thymocytes (Fig. 5D).

To examine whether the action of lovastatin on efferocytosis in vivo was HMG-CoA reductase dependent, mice were treated with...
Lovastatin (10 mg/kg), three times over 30 h, in the presence or absence of rescue mevalonate, and clearance of apoptotic thymocytes by alveolar macrophages was assessed. Lovastatin again increased efferocytosis by alveolar macrophages in vivo, and this effect was prevented by mevalonate (Fig. 5E). Together, these results indicate that lovastatin enhances efferocytosis in the naive murine lung in an HMG-CoA reductase-dependent manner, thus confirming in vitro results.

Lovastatin enhances efferocytosis by human alveolar macrophages taken from patients with COPD

Accumulating evidence suggests that efferocytosis is dysregulated in chronic inflammatory lung diseases, such as COPD, and may contribute to disease pathogenesis. For example, several animal models of COPD are associated with increased accumulation (58–61) and impaired removal (45) of apoptotic cells. Likewise, apoptotic cells are increased in COPD lungs (31, 62–65) and efferocytosis is defective in COPD alveolar macrophages ex vivo (32). Therefore, we tested the effect of lovastatin on efferocytosis by alveolar macrophages isolated from GOLD stage 2 (66) COPD patients (Table I). Lovastatin enhanced efferocytosis in these alveolar macrophages in an HMG-CoA reductase-dependent manner (Fig. 6). Taken together, these data suggest that statins may have therapeutic potential in diseases, such as COPD, where efferocytosis is suppressed and inflammation is dysregulated.

Discussion

Apoptotic cell clearance defects are increasingly recognized in diseases of chronic inflammation (31, 32) and autoimmunity (33, 34, 67, 68), suggesting that effective efferocytosis may be necessary for the maintenance of homeostasis. This concept is based on the role efferocytosis plays in suppressing both the innate (69, 70) and adaptive (68) immune response and in removing autoantigens (71). Interestingly, this concept is not new. Over 100 years ago, Metchnikoff (72) recognized this removal process and its importance to homeostasis, which he termed “physiologic inflammation.” Therefore, therapies that enhance efferocytosis may offer a unique therapeutic benefit, especially if impaired efferocytosis is a determinant of disease pathogenesis. Our findings indicate that lovastatin enhances efferocytosis in vitro and in vivo. Lovastatin’s effect on efferocytosis depends on its ability to inhibit HMG-CoA reductase, decrease prenylation substrates, and to alter the balance of Rho GTPases. Lovastatin may have therapeutic potential in chronic inflammatory diseases with impaired efferocytosis because it reverses impaired efferocytosis in vitro and in vivo, and enhances efferocytosis by alveolar macrophages from patients with COPD.

Up to 2% of expressed cellular proteins are prenylated and over 150 prenylated proteins have been identified (73, 74), suggesting that the effect of statins on efferocytosis is likely to be complex. Our findings indicate that lovastatin enhanced efferocytosis in vitro, in part, by altering the membrane balance of RhoA and Rac-1, two key regulators of efferocytosis. Geranylgeranylation and farnesylation.

Lovastatin-enhanced efferocytosis is dependent on geranylgeranylation and farnesylation. A, GGPP (1, 5, and 10 μM) and (D) FPP (5 and 10 μM) prevented lovastatin from increasing efferocytosis of apoptotic human neutrophils by HMDMs, but 10 μM GGPP or FPP alone had no effect on efferocytosis. The mean PI as a percentage of control ± SEM is shown for five replicates per group. Control mean PI: 3.8 ± 0.8. * Significantly different from control (p < 0.05). C, GGTTI-2133 (20 and 40 nM) and (D) FTI-276 (0.5 nM) enhanced efferocytosis of apoptotic human neutrophils by HMDMs. As a positive control, HMDMs were treated with 10 μM lovastatin for 24 h. DMSO vehicle had no effect on efferocytosis. The mean PI as a percentage of control ± SEM is shown for 3–10 replicates/group. Control mean PI for C: 3.9 ± 0.3, and D: 4.9 ± 1.0. * Significantly different from control (p < 0.05).
prolonged effect include: 1) geranylgeranyltransferase I may prenylate Rac-1 more efficiently than RhoA, or 2) prenylation of Rac-1 may be less substrate dependent. Even during lovastatin treatment, prenylation substrates (GGPP or FPP) would be expected to be present in small quantities due to incomplete blockade of HMG-CoA reductase, or due to salvage pathway activity (75). Alternatively, 3) the half-life of prenylated Rac-1 may be longer than prenylated RhoA. This possibility is less likely, because lovastatin enhanced efferocytosis as long as 5 days after treatment. We also noted that the ability of lovastatin to increase efferocytosis by HMDMs waned during days 3 and 4 of treatment, but increased again at day 5. We do not have a clear explanation for this observation, but it was consistent across both concentrations tested.

Our data suggest that farnesylated proteins might negatively regulate efferocytosis, because inhibition of farnesyltransferase modestly increased efferocytosis, and FPP repletion reversed lovastatin-enhanced efferocytosis. RhoB is an attractive candidate for this effect, because it is both farnesylated and geranylgeranylated (76) and it plays a known role in the phagocytosis of Pneumocystis (77). Whether farnesyltransferase inhibitors also shift the balance toward production of other geranylgeranylated proteins that could enhance efferocytosis, like Rac-1, Cdc42, or RhoG (43, 78), remains to be determined.

Growing evidence from animal models indicates that statins may have a role in the treatment of inflammatory lung diseases, including acute lung injury (2), asthma (18), and emphysema (19). Our data supports this notion, because lovastatin increased efferocytosis in the lungs of naive mice. In vivo, lovastatin may enhance efferocytosis by altering the balance of membrane-bound RhoA and Rac-1, as was demonstrated in vitro. Alternatively, in vivo and especially in an inflammatory environment, lovastatin may enhance efferocytosis by suppressing oxidative stress, because oxidative stress inhibits efferocytosis by activating RhoA (K. A. McPhillips, manuscript in preparation). Lovastatin also suppresses matrix metalloproteinase-9 (8), which inhibits efferocytosis in vitro (R. W. Vandivier, unpublished data), and is an important component of lung inflammation. Finally, statins increase PPARγ, which has also been shown to increase efferocytosis (79).

Lovastatin did not enhance efferocytosis by altering apoptotic cell binding or by increasing expression of efferocytosis receptors. In contrast, Ruiz-Velasco et al. (55) found that lovastatin treatment (10 μM) increased CD36 surface expression and mRNA in human monocytes at 24 h and THP-1 cells at 48 h. The disparity between our findings may relate to intrinsic differences between human monocytes and HMDMs.

Lovastatin suppressed FcγR-mediated phagocytosis in an HMG-CoA reductase-dependent manner, confirming recent reports (53, 54). Interestingly, these authors all concluded that statins suppress FcγR-mediated phagocytosis by inhibiting cholesterol
biosynthesis, and not by inhibiting prenylation (53, 54). Like efferocytosis, prenylated proteins like Rac-1, Cdc42, and Rab11 are required for FcγR-mediated phagocytosis (80, 81), and a role for RhoA has been suggested (82). Therefore, we propose that under certain conditions statins might also influence FcγR phagocytosis through modulation of Rho GTPases. The effect of statins on FcγR-mediated phagocytosis is concerning because of its potential to impair host defense, but ultimately, its importance remains to be demonstrated in vivo. In a Klebsiella pneumoniae mouse model of pneumonia, lovastatin delayed bacterial clearance and enhanced dissemination (2). In contrast, statins have consistently improved survival in animal and human bacterial sepsis (16, 22, 83), implying that the beneficial effects of statins may outweigh their potential deleterious effects.

The dose and concentration of lovastatin used in the in vitro and in vivo experiments is certainly higher than is used clinically, suggesting that lovastatin may not augment efferocytosis when used in humans. In mice, however, lovastatin induces a 6- to 10-fold increase in hepatic microsomal HMG-CoA reductase after only 24 h, implying that higher doses may be required to produce clinical effects in mice compared with humans (48). In humans, prolonged administration of lovastatin at 80 mg/kg/day results in steady state concentrations ranging from 0.15 to 0.3 μM (84), which is marginally less than the lowest effective concentration of lovastatin used in our study (1 μM). The effectiveness of lovastatin in vivo, though, may depend on the clinical setting and remains to be determined in COPD. For example, it is possible that prolonged lovastatin treatment at clinically relevant doses may augment efferocytosis in humans with COPD, especially if RhoA activity is increased.

Figure 6. Lovastatin reverses impaired efferocytosis in COPD alveolar macrophages ex vivo. Human alveolar macrophages were isolated from patients with GOLD stage 2 COPD, then incubated with or without lovastatin or mevastatin for 24 h before coculture with apoptotic human neutrophils. Lovastatin (Lova; 10 μM) treatment enhanced efferocytosis by GOLD stage 2 alveolar macrophages (n = 3), but not in the presence of mevastatin (l-Meva; 50 μM). Control mean PF: 5.5 ± 1.9. * Significantly different from control (p < 0.05).

The ability of statins to enhance efferocytosis suggests a new mechanism by which statins may modulate acute and chronic inflammatory diseases, and may help direct statin clinical trials to specific diseases. For example, cystic fibrosis, bronchiectasis, and COPD are attractive targets for statin therapy because they are all associated with accumulation, and defective clearance, of apoptotic cells (31, 32). Indeed, our data provides “proof of principle” for this approach because lovastatin increased efferocytosis by human alveolar macrophages taken from patients with COPD. Lee et al. (19) have also shown that statin treatment inhibits the development of cigarette smoke-induced emphysema in rats. However, we would not suggest that potential therapeutic targets be limited to these chronic inflammatory lung diseases, because accumulation of apoptotic cells and failed efferocytosis has also been implicated in systemic inflammatory diseases, like glomerulonephritis (34), rheumatoid arthritis (36), and systemic lupus erythematosus (35).

Disclosures
The authors have no financial conflict of interest.

References


